A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia
NCT07037771
Recruiting
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug durin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/03/2025
Locations: Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235
Recruiting
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/03/2025
Locations: Cahaba Dermatology & Skin Health Center ( Site 0012), Birmingham, Alabama +11 locations
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Scottsdale, AZ, Scottsdale, Arizona +116 locations
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Imaging Studies in Corticobasal Syndrome
NCT07000851
Recruiting
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Register for Updates
Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects
NCT07015671
Recruiting
This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/03/2025
Locations: Sarfez Pharmaceuticals, Vienna, Virginia
Conditions: Bioequivalence Study in Healthy Subjects, PK/PD
Register for Updates
Video-feedback Intervention to Promote Racial-Ethnic Socialization Competency (VIP-RACE)
NCT07055906
Recruiting
The aim of this study is to evaluate a novel cultural strengths parenting program - the Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE) - which seeks to support Latine parents' motivation to engage in racial-ethnic socialization (RES) and strengthen their RES competency (improved skills and confidence, decreased stress). In the preliminary phases of this project, we iteratively refined the VIP-RACE program in partnership with advisory boards of youth, par... Read More
Gender:
ALL
Ages:
Between 10 years and 14 years
Trial Updated:
07/03/2025
Locations: Parents and Children Together (PACT) Lab Space, Harrisburg, Pennsylvania
Conditions: Depressive Symptoms, Anxiety Symptoms, Conduct Problems
Register for Updates
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
NCT07063212
Recruiting
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation
NCT07065669
Recruiting
This is a pilot study to examine the tolerability, safety and early efficacy of two forms of transcranial magnetic stimulation (TMS) for treating adolescents with Obsessive Compulsive Disorder (OCD) who have experienced limited improvements with usual treatments for OCD in adolescents. The project's primary goal is to examine whether adolescents can complete 3 consecutive weeks of TMS administered 5 days per week, and to describe the type of and how common individual side effects with TMS occur... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
07/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Real-time NOMA Evaluation
NCT06996626
Recruiting
Alerts related to outlier clinician behavior are generated in real-time by an intelligent system continuously scraping EHR (electronic health record) data. These alerts are passed to the bedside and their potential impact on bedside clinical behavior is evaluated.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/03/2025
Locations: UPMC Montefiore, Pittsburgh, Pennsylvania +1 locations
Conditions: Critical Illness
Register for Updates
Serial Blood Count Study
NCT07066085
Recruiting
The objective of the Serial Blood Count Study is to determine the utility of home monitoring of white blood cell (WBC) and absolute neutrophil counts (ANC) to diagnose cyclic neutropenia and distinguish between cyclic and severe congenital neutropenia (SCN). A new home monitoring device called Athelas One was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC). The investigators believe this device provides a unique and extremely va... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/03/2025
Locations: University of Washington Medical Center - Montlake, Seattle, Washington
Conditions: Cyclic Neutropenia, Congenital Neutropenia, Neutropenia
Register for Updates
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800
Recruiting
In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoa... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: Academic Medical Research Institute, Los Angeles, California +2 locations
Conditions: Primary Membranous Nephropathy
Register for Updates
Transcutaneous Electrical Nerve Stimulation (TENS) for Intrauterine Device (IUD) Insertion Pain
NCT07044622
Recruiting
This study is a double-blind, randomized, placebo-controlled trial to evaluate the use of high frequency TENS for pain control during IUD insertion. Transcutaneous electrical nerve stimulation (TENS) is a relatively low-cost, low-risk, non-pharmacologic intervention for pain management. Previous studies have found that TENS reduces pain associated with other outpatient gynecological procedures. Participants will be randomized in a 1:1 ratio to either active treatment or placebo (placebo TENS) an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Center for Women's Health and Midwifery, New Haven, Connecticut +1 locations
Conditions: Pain
Register for Updates